• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » INC Research acquires Australian CRO Trident

INC Research acquires Australian CRO Trident

June 3, 2011
CenterWatch Staff

Raleigh, N.C.-based INC Research, a therapeutically focused CRO, has acquired Australian CRO Trident Clinical Research to expand its clinical trials outsourcing footprint and expertise in Australia, New Zealand and India.

Trident will become a wholly owned affiliate of INC Research and will operate as Trident Clinical Research, an INC Research company, through its offices in Sydney, Brisbane, Melbourne, Adelaide, Auckland and Mumbai. Trident’s operation in Mumbai will increase the reach of INC Research’s already sizeable clinical and data operations located in Gurgaon, India.

“Trident is an important piece in our strategy to build a sustainable CRO business that both satisfies and anticipates the global drug development needs of our customers,” said James Ogle, CEO of INC Research.

Founded in 1997, Trident has strategically grown to become one of Australia’s largest CROs with more than 100 employees across three countries, a range of services and diverse therapeutic experience, with more than 500 clinical studies completed across phases I to IV, including over 100 phase I studies.

Based on data from the Economist Intelligence Unit, Australia offers significant cost advantages, has a highly efficient regulatory system and is a desirable location to conduct early-phase clinical trials. Australia achieves rapid study timelines without the need for IND or CTA, and is attracting first-in-man and early-phase clinical studies. Trident designs and reports phase I trials as well as manages advanced phase I facilities, leveraging Australia’s streamlined regulatory process to drive efficiencies for its customer’s projects.

“The R&D opportunities in Australia, New Zealand and India for cost-effective local and global drug development programs are enormous,” said Garth Tierney, managing director and co-founder of Trident Clinical Research, who will assume the role of Regional General Manager, Australasia, at INC Research.

 

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing